Advertisement
Articles
Advertisement

Focus On Funding 8/26/05

Fri, 08/26/2005 - 6:27am


GOVERNMENT FUNDING
NCI Awards $14M to UC Davis
The National Cancer Institute renewed its designation of the University of California Davis Cancer Center for five years, which includes $14 million in new federal funding through 2010 to support the center's research program being performed on 317 cancer projects on three campuses.
Full Article

CureLab Receives $7M NIH Grant
CuraLab Inc., Boston, will receive a grant of up to $7 million from the National Institutes of Health to continue its work developing a vaccine against the influenza virus that would be effective against all strains of flu, the first phase of a two-phase grant under the Small Business Innovation Research Bio Defense Program.
Full Article

NIH Funds Three New Stem Cell Research Centers
The National Institute of General Medicine Sciences, part of the National Institutes of Health (NIH), funded three new Exploratory Centers for Human Embryonic Stem Cell Research, which will receive an estimated $9 million over three years. The centers, Mount Sinai School of Medicine, New York, Albert Einstein College of Medicine, New York, and the Burnham Institute, La Jolla, Calif., are limited to using federally approved stem cell lines listed on the NIH Human Embryonic Stem Cell Registry.
Full Article

Scripps Receives $4.2M to Speed DNA Sequencing Technologies
The National Human Genome Research Institute, part of the National Institutes of Health, awarded The Scripps Research Institute, La Jolla, Calif., and Oxford University, UK, a $4.2 million five-year grant to conduct research aimed at speeding the rate at which the next generation of DNA sequencing technologies will become available in order to develop technology to sequence a single piece of DNA.
Full Article

NHGRI Awards $32M for Innovative Sequencing
The National Human Genome Research Institute, part of the National Institutes of Health, awarded grants totaling more than $32 million to a number of research groups to advance the development of innovative technologies intended to reduce the cost of DNA sequencing and expand the use of genomics in biomedical research and health care. Its near-term goal is to lower the cost of sequencing a mammalian-sized genome to $100,000.
Full Article

PRIVATE FUNDING
NeoRX Makes First Corporate Investment in Scripps Florida
NeoRx Corp., Seattle, will invest $2.5 million into research at Scripps Florida over the next 26 months to develop anti-cancer and other drugs. NeoRx will have exclusive global rights to commercialize the compounds developed through the partnership. This collaboration marks the first corporate investment in the new Scripps Florida research center.
Full Article

Aureon Labs Secures $20M in Capital Funding
Aureon Laboratories (formerly Aureon Biosciences), Yonkers, N.Y., closed on $20 million worth of venture capital financing. The company specializes in next-generation tissue analysis by integrating clinical, micro-anatomic, and molecular profiles of disease, initially in the field of prostate cancer.
Full Article

Mpex Pharmaceuticals Closes $32M in Financing
Mpex Pharmaceuticals Inc., San Diego, a biopharmaceutical company discovering and developing antibacterials to treat life-threatening infections, announced a $32 million private placement of its Series B preferred stock. Mpex also raised $3.7 million from the sale of common and Series A preferred stock.
Full Article

Avontec Raises €14.5M for Asthma and Psoriasis Research
Avontec GmbH, Munich, Germany, raised 14.5 million euros in a Series B round of financing for two phase IIa clinical trials in moderate-to-severe asthma and psoriasis. The biopharmaceutical company develops new anti-inflammatory approaches using its innovative Decoy Oligonucleotide Technology.
Full Article

Cerenis Therapeutics Receives $30.5M in International Financing
Cerenis Therapeutics SA, Ann Arbor, Mich., a pharmaceutical company created in March 2005 to discover, develop, and commercialize breakthrough high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases, completed a $30.5 million equity financing round from an international syndicate represented by France, Sweden, the United States, and Japan. This financing represents one of the largest early stage private equity financings among life science companies this year.
Full Article

Remicade Founder Pledges $105M to NYU School of Medicine
Jan Vilcek, MD, PhD, a professor of microbiology and a member of the New York University School of Medicine faculty for more than 40 years, pledged $105 million to the School of Medicine, the largest gift ever made to the school and believed to be the largest philanthropic gift from an active faculty member to an academic medical center. Vilcek pledged the gift from royalties earned from Remicade, an anti-inflammatory drug for which he developed the monoclonal antibody while working in the school's Department of Microbiology.
Full Article

GRANTS AVAILABLE
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) and its Complications
Agency: National Institute of Diabetes, Digestive and Kidney Diseases; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Neurological Disorders and Stroke; and National Institute of Child Health and Human Development
Estimated Funding: $4M
Due Date for Applications: Mar 15, 2006
Description: The participating institutes invite the small businesses to apply cutting edge technology to investigate the development of new approaches to predict, prevent, treat, and cure type 1 Diabetes and its complications.
Full Announcement

Biology of RNA Interference: Stability, Delivery, and Processing by Tissues
Agency: National Heart, Lung, and Blood Institute; the National Institute of Neurological Diseases and Stroke; the National Institute of Allergy and Infectious Diseases; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of General Medical Sciences; and the National Institute of Dental and Cranofacial Research
Estimated Funding: $5.6M
Due Date for Applications: January 18, 2006
Description: This RFA supports research projects to improve uptake, stability, processing, and delivery of RNAi specific to target tissues and specific cell types.
Full Announcement

Alzheimer's Disease Drug Development Program
Agency: National Institute on Aging
Estimated Funding: $4M
Due Date for Applications: Multiple receipt dates, see Link to Full Announcement for details.
Description: The objective is to stimulate research in pre-clinical development and testing of novel therapeutic compounds aimed at slowing, halting, or reversing the decline in cognitive function and modifying behavioral symptoms in Alzheimer's disease, preventing or delaying its onset.
Full Announcement

In Vivo Cancer Imaging Exploratory/Developmental Grants
Agency: National Cancer Institute
Estimated Funding: Amount Not Available
Due Date for Applications: Multiple receipt dates, see Link to Full Announcement for details.
Description: This PA seeks applications that articulate exploratory/developmental research focused on in vivo cancer imaging from basic discovery of new cancer imaging agents and technologies, through pre-clinical testing and validation.
Full Announcement

Animal Models of Diabetic Complications Consortium
Agency: Department of Health and Human Services, National Institutes of Health
Estimated Funding: $5.25M
Due Date for Applications: November 18, 2005
Description: This RFA is for pathobiology sites to support years 6 to10 of the Animal Models of Diabetic Complications Consortium, to generate and phenotype new models of diabetic complications.
Full Announcement

New Ways to Image Neural Activity
Agency: National Institutes of Health
Estimated Funding: $1.5M
Due Date for Applications: October 25, 2005
Description: This RFA is intended to support research leading to new ways for high resolution imaging of neural activity reflected in electrophysiological signals.
Full Announcement


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading